Home Ablative Solutions Inc.

Ablative Solutions Inc.

Peregrine Post-Market Study Published in the Journal of the American College of Cardiology: Cardiovascular Interventions

Peregrine Post-Market Study is a European multicenter open-label trial that evaluated additional safety and performance of the Peregrine System Infusion Catheter using a neurolytic agent (dehydrated alcohol) delivered into the space outside of the renal (kidney) arteries in 45 patients with systemic hypertension.

Ablative Solutions Announces $77 Million Financing for Unique Therapeutic Approach to Treating Uncontrolled Hypertension

1/3/19: The company pioneering new approaches for the treatment of hypertension. Today the company announced the first close of its $77 million Series D funding round. The round was led by new investor Gilde Healthcare and co-led by existing investor BioStar Ventures and an undisclosed new strategic corporate investor. Existing investors including Michigan Accelerator Fund, Novus Biotechnology and other individual investors also participated the Series D funding round.